![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 21, 2022 10:12:40 PM
Also, glad to see the uplisting seems to be going smoothly so far!
~ posted by Major, Y@h00 RLFTF finance conversations
Geneva, Switzerland, March 21, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced the appointment of Christopher Wick to the newly created position of Senior Director, Head of U.S. Sales. In this position, Mr. Wick will be responsible for building out and leading the company’s U.S. sales team.
“The expansion of our pipeline and commercialized product portfolio, garnered as a result of our collaboration with Acer Therapeutics and the strategic acquisition, last year, of APR Applied Pharma Research SA, have allowed us to proactively plan for U.S. market penetration, initially, for APR’s currently marketed flagship PKU GOLIKE® to treat phenylketonuria and the potential launch of ACER-001 to treat Urea Cycle Disorders, which has a Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2022 ,” stated Raghuram (Ram) Selvaraju, Chairman of Relief. “In this new position, Christopher will work closely with our Head of U.S. Commercial Operations, Anthony Kim, to build our capabilities in this all important market, in order to ensure our commercial success. His highly impressive background, punctuated by extraordinary sales success during more than 20 years at ‘big pharma,’ including with Alexion Pharmaceuticals, GlaxoSmithKline and Novartis, makes Christopher a highly coveted addition to our team.”
Prior to joining Relief, Mr. Wick was, since 2018, Regional Sales Director for Alexion Pharmaceuticals, Inc., where he developed and led two high performing Excellence Award winning teams which achieved best in the nation sales for two product launches of Soliris®, for the treatment of neuromyelitis optica spectrum disorder (NOSD) and generalized myasthenia gravis (gMG). Earlier, from 2015 to 2018, he served as the company’s Southwest Regional Account Manager, where he cultivated a regional key opinion leader physician network while launching two of Alexion’s enzyme replacement therapies for ultra-rare disease.
From 2007 until 2015, Mr. Wick served in positions of increasing responsibility at GlaxoSmithKline, most recently, from 2012 to 2015, as Southwest Health Systems Account Manager helping to ensure early adoption of the company’s launch products as well as the entire pharmaceutical and biologic portfolio. In that role, he was responsible for Hospital System contracts, and collaborating with GlaxoSmithKline’s largest and most complex accounts in the Integrated Delivery Networks (IDN) and Hospital Customer Segment.
Earlier, from 1999 until 2007, Mr. Wick was an Executive Account Manager at Novartis. While there, he contributed to both Specialty and Hospital Sales, served as a National Training Leader and Regional Trainer and consistently achieved a top 15% sales ranking.
Mr. Wick attended Purdue University and earned a Bachelor of Arts in Business Administration from New Mexico State University.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM